Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 27, 2015 Research and Markets( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:5/28/2015)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... institutional healthcare investors to purchase an aggregate of approximately ... at-the-market registered direct offering and a concurrent private placement ... Company entered into a definitive purchase agreement with these ... an aggregate of 3,000,000 shares of its common stock ...
(Date:5/28/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... therapeutics, primarily in the areas of dermatology and ophthalmology, ... 26 million units at a price to the public ... $10.4 million. Each unit consists of (i) one share ... to purchase 0.50 of a share of common stock ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Aug. 16, 2011 Quanterix Corporation, a company ... based on its revolutionary Si ngle ... STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX), ... of automated analyzer systems, today announced an agreement ...
... The Society of Interventional Radiology Foundation launched a ... the future of the specialty with its announcement ... student conducting preclinical research in interventional radiology during ... prestigious Medical Research Fellows Program. (Logo: ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today that the Company has ... of Defense (DoD) Broad Agency Announcement for studies directed ... the bioproduction of its nerve agent medical countermeasure program. ...
Cached Biology Technology:Quanterix and STRATEC Announce Strategic Partnership 2Quanterix and STRATEC Announce Strategic Partnership 3Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 2Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 2Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 4
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... of Nature Chemistry , ASU scientists, along with ... perfecting a functional artificial leaf. Designing an artificial ... and efficiently into hydrogen and oxygen is one of ... Center, funded by the Department of Energy, in the ...
... that packs twice the energy compared to current microbatteries used ... Pacific Northwest and around the world. The battery, a ... is certainly not the world,s smallest battery, as engineers have ... hair. But those smaller batteries don,t hold enough energy to ...
... Led by biomedical engineer Justin Zook of the National ... from Harvard University and the Virginia Bioinformatics Institute ... methods to integrate data from different sequencing platforms, thus ... genome sequencing. "Understanding the human genome is an ...
Cached Biology News:Artificial leaf jumps developmental hurdle 2A battery small enough to be injected, energetic enough to track salmon 2A battery small enough to be injected, energetic enough to track salmon 3A battery small enough to be injected, energetic enough to track salmon 4Research team establishes benchmark set of human genotypes for sequencing 2
...
... Materials for 15-20 enhancements when used as directed, ... Enhancement System is designed to amplify the desired signal ... for evaluating proteins with low expression., ... to blocking the membrane; 1x solution; 250 ml, ...
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: